Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 616 to 630 of 1553 results for do not do recommendations

  1. Looked-after children and young people (QS31)

    This quality standard covers the health and wellbeing of looked-after children and young people (from birth to 18 years) and care leavers (including young people planning to leave care or under leaving care provisions). It is for all settings and services that work with and care for looked-after children and young people, wherever they are living (for example, with family or friends, with foster families or in residential care). It describes high-quality care in priority areas for improvement.

  2. How can providers and healthcare professionals identify groups that do not initially engage, or do not stay engaged, with digital and mobile health behaviour change interventions?

    Recommendation ID NG183/1 Question How can providers and healthcare professionals identify groups that do not initially...

  3. How do socioeconomic, environmental, biological and psychosocial factors determine diet and physical activity behaviours and how do they contribute to differences in the risk of developing type 2 diabetes?

    Recommendation ID PH35/4 Question How do socioeconomic, environmental, biological and psychosocial factors determine diet...

  4. Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

    Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.

  5. Symptoms and signs of long-term (chronic) UTI: What symptoms and signs do children and young people with long-term (chronic) UTI report and what do they perceive is the impact on their health and quality of life?

    Recommendation ID NG224/04 Question Symptoms and signs of long-term (chronic) UTI: What symptoms and signs do children and...

  6. Are the Department of Health's 'Let's get moving' physical activity care pathway and the general practice physical activity questionnaire (GPPAQ) both commonly used in primary care? How do primary care practitioners view GPPAQ and, if they do not use it, why not?

    Recommendation ID PH44/7 Question Are the Department of Health's 'Let's get moving' physical activity care pathway and the general...

  7. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA1042)

    Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults.

  8. What key factors influence the effectiveness of population-level or whole-area approaches to encouraging walking or cycling? How do these factors interact?

    Recommendation ID PH41/2 Question What key factors influence the effectiveness of population-level or whole-area approaches to...

  9. Antisocial behaviour and conduct disorders in children and young people: recognition and management (CG158)

    This guideline covers recognising and managing antisocial behaviour and conduct disorders in children and young people aged under 19. It aims to improve care by identifying children and young people who are at risk and when interventions can prevent conduct disorders from developing. The guideline also makes recommendations on communication, to help professionals build relationships with children and young people and involve them in their own care.

  10. Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.

  11. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

    Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.

  12. Mirabegron for treating symptoms of overactive bladder (TA290)

    Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.

  13. Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)

    Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.

  14. Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment (HTG759)

    Late stage assessment (LSA) guidance on bed frames for adults in acute medical or surgical hospital wards.